Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 18060
Country/Region: Tanzania
Year: 2016
Main Partner: Elizabeth Glaser Pediatric AIDS Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $8,907,563 Additional Pipeline Funding: $7,228,688

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: TB/HIV (HVTB) $527,174
Care: Pediatric Care and Support (PDCS) $268,167
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $7,013,672
Treatment: Pediatric Treatment (PDTX) $1,098,550
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 1,390
GEND_GBV Age/Sex: <10 Male 2017 1,267
GEND_GBV Age/Sex: 10-14 Female 2017 2,214
GEND_GBV Age/Sex: 10-14 Male 2017 1,554
GEND_GBV Age/Sex: 15-19 Female 2017 1,163
GEND_GBV Age/Sex: 15-19 male 2017 1,138
GEND_GBV Age/Sex: 20-24 Female 2017 887
GEND_GBV Age/Sex: 20-24 Male 2017 740
GEND_GBV Age/Sex: 25-49 Female 2017 1,114
GEND_GBV Age/Sex: 25-49 Male 2017 939
GEND_GBV Age/Sex: 50+ Female 2017 127
GEND_GBV Age/Sex: 50+ Male 2017 92
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 531
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 8,419
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 4,206
GEND_GBV Number of people receiving post-GBV care 2017 12,625
GEND_GBV Sum of Age/Sex Disaggregates 2017 6,425
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 40,181
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 52,254
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 450,781
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 155,930
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 699,146
HTS_TST Service Delivery Point (Facility): Inpatient 2017 24,656
HTS_TST Service Delivery Point (Facility): Other PITC 2017 17,503
HTS_TST Service Delivery Point (Facility): Outpatient 2017 263,683
HTS_TST Service Delivery Point (Facility): Pediatric 2017 85,327
HTS_TST Service Delivery Point (Facility): PMTCT 2017 307,977
HTS_TST Sum of Aggregated Age/Sex <15 2017 92,435
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 606,711
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 699,146
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 833
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 880
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 12,665
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 6,345
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 30
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 2
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 63
LAB_PT CD4: Number of laboratories that perform this testing 2017 2
LAB_PT CD4: Number of laboratories that perform this testing 2017 77
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 165
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 130
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 164
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 166
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 165
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 187
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 6
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 109
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 109
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 120
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 6
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 6
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 7
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2,206
PMTCT_ART New on ART 2017 4,917
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 303,181
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 5,407
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,719
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 46
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 155
PMTCT_EID Sum of Infant Age disaggregates 2017 7,126
PMTCT_STAT By: Known positives at entry 2017 2,318
PMTCT_STAT By: Number of new positives identified 2017 5,174
PMTCT_STAT Number of new ANC and L&D clients 2017 319,152
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 303,181
PMTCT_STAT Sum of Positives Status disaggregates 2017 7,492
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 1,899
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 19
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 1,688
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 192
TB_SCREENDX Screen Result: Screened Positive for TB 2017 1,899
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 78,597
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 34,510
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 4,905
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 4,712
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 122,724
TX_CURR Aggregated Age/Sex: <15 Female 2017 4,298
TX_CURR Aggregated Age/Sex: <15 Male 2017 5,008
TX_CURR Aggregated Age/Sex: 15+ Female 2017 82,365
TX_CURR Aggregated Age/Sex: 15+ Male 2017 37,541
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 129,212
TX_CURR Sum of Aggregated Age/Sex <15 2017 9,306
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 119,906
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 129,212
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,128
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,069
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 18,974
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 8,184
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 29,355
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 29,355
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 80,636
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 72,653
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,619
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2,754
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 46,334
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 20,946
TX_PVLS Numerator: Indication: Routine 2017 26,511
TX_PVLS Numerator: Indication: Targeted 2017 46,142
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 2,883
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,034
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 51,473
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 23,246
TX_PVLS_den Denominator: Indication: Routine 2017 29,355
TX_PVLS_den Denominator: Indication: Targeted 2017 51,281
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 742
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 696
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9,442
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,330
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 15,210
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 20,294
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 980
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 925
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12,594
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,795
Cross Cutting Budget Categories and Known Amounts Total: $1,213,352
Gender: Gender Based Violence (GBV) $380,376
Post GBV Care
Gender: Gender Equality $782,976
Increase gender-equitable access to income and productive resources, including education
Water $50,000